Table 1.

Final bodyweights and relative liver and spleen weights

Group	TAA	MeIQx (p.p.m.)	Number of rats	Initial bodyweight (g)	Final bodyweight (g)	Relative organ weight (%)
						Liver	Spleen
1	+	0	30	120.9 ± 5.4	331.1 ± 24.4**	3.2 ± 1.1*	0.2 ± 0.1*
2	+	0.001	30	118.8 ± 5.2	334.4 ± 23.3**	3.2 ± 1.1*	0.3 ± 0.1*
3	+	0.01	30	120.5 ± 5.6	331.5 ± 20.9**	3.4 ± 1.3**	0.3 ± 0.1**
4	+	0.1	30	121.9 ± 5.2	339.2 ± 21.0**	3.0 ± 0.8	0.2 ± 0.1
5	+	1	30	120.7 ± 5.5	337.6 ± 20.8**	2.9 ± 0.8	0.2 ± 0.1
6	+	10	30	120.2 ± 4.9	343.6 ± 19.7**	2.9 ± 0.6	0.2 ± 0.0
7	+	100	29	121.2 ± 5.0	326.0 ± 16.3**	3.3 ± 0.7	0.3 ± 0.1*
8	–	0	10	119.5 ± 6.8	390.8 ± 11.9	2.1 ± 0.1	0.2 ± 0.0
9	–	0.001	10	119.0 ± 6.0	404.8 ± 19.2	2.1 ± 0.1	0.2 ± 0.0
10	–	0.01	10	117.9 ± 4.9	403.9 ± 14.8	2.1 ± 0.1	0.2 ± 0.0
11	–	0.1	10	118.1 ± 5.5	399.5 ± 27.2	2.1 ± 0.2	0.2 ± 0.0
12	–	1	10	118.9 ± 3.1	399.5 ± 18.8	2.1 ± 0.1	0.2 ± 0.0
13	–	10	10	119.3 ± 5.9	394.5 ± 18.1	2.1 ± 0.1	0.2 ± 0.0
14	–	100	10	118.1 ± 6.2	389.9 ± 21.3	2.3 ± 0.1	0.2 ± 0.0

Data represent the mean ± SD. *,** Significantly different from the corresponding control group without thioacetamide (TAA) at P < 0.05 and P < 0.01, respectively. MeIOx, 2‐amino‐3,8‐dimethylimidazo[4,5‐f]quinoxaline.